US20070004780A1 - Treatment of Diabetes with Thiazolidinedione and Metformin - Google Patents
Treatment of Diabetes with Thiazolidinedione and Metformin Download PDFInfo
- Publication number
- US20070004780A1 US20070004780A1 US11/469,530 US46953006A US2007004780A1 US 20070004780 A1 US20070004780 A1 US 20070004780A1 US 46953006 A US46953006 A US 46953006A US 2007004780 A1 US2007004780 A1 US 2007004780A1
- Authority
- US
- United States
- Prior art keywords
- compound
- administration
- pharmaceutically acceptable
- metformin
- diabetes mellitus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- This invention relates to a method of treatment, in particular to a method for the treatment of diabetes mellitus, especially non-insulin dependent diabetes (NIDDM) or Type II diabetes and conditions associated with diabetes mellitus.
- NIDDM non-insulin dependent diabetes
- Biguanide antihyperglycaemic agents are commonly used in the treatment of NIDDM (or Type II diabetes).
- 1,1-Dimethylbiguanidine (or Metformin) is an example of a biguanides antihyperglycaemic agent.
- European Patent Application, Publication Number 0,306,228 relates to certain thiazolidinedione derivatives disclosed as having antihyperglycaemic and hypolipidaemic activity.
- One particular thiazolidinedione disclosed in EP 0306228 is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter ‘Compound (I)’).
- WO94/05659 discloses certain salts of Compound (I) including the maleate salt at example 1 thereof.
- Compound (I) is an example of a class of anti-hyperglycaemic agents known as ‘insulin sensitisers’.
- Compound (I) is a thiazolidinedione insulin sensitiser.
- acyclic insulin sensitisers Another series of compounds generally recognised as having insulin sensitiser activity are those typified by the compounds disclosed in International Patent Applications, Publication Numbers WO93/21166 and WO94/01420. These compounds are herein referred to as ‘acyclic insulin sensitisers’. Other examples of acyclic insulin sensitisers are those disclosed in U.S. Pat. No. 5,232,945 and International Patent Applications, Publication Numbers WO92/03425 and WO91/19702.
- insulin sensitisers examples include those disclosed in European Patent Application, Publication Number 0533933, Japanese Patent Application Publication Number 05271204 and U.S. Pat. No. 5,264,451.
- Compound (I) in combination with a biguanide antihyperglycaemic agent provides a particularly beneficial effect on glycaemic control with no observed adverse effects, such combination is therefore particularly useful for the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus.
- the invention provides a method for the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus in a mammal, such as a human, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser, such as Compound (I), and a biguanide antihyperglycaemic agent, to a mammal in need thereof.
- an insulin sensitiser such as Compound (I)
- a biguanide antihyperglycaemic agent a mammal in need thereof.
- the invention provides an insulin sensitiser, such as Compound (I), together with a biguanide antihyperglycaemic agent, for use in a method for the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus.
- an insulin sensitiser such as Compound (I)
- a biguanide antihyperglycaemic agent for use in a method for the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus.
- the method comprises either co-administration of an insulin sensitiser, such as Compound (I), and a biguanide antihyperglycaemic agent or the sequential administration thereof.
- an insulin sensitiser such as Compound (I)
- a biguanide antihyperglycaemic agent or the sequential administration thereof.
- Co-administration includes administration of a formulation which includes both an insulin sensitiser, such as Compound (I), and a biguanide antihyperglycaemic agent or the essentially simultaneous administration of separate formulations of each agent.
- an insulin sensitiser such as Compound (I)
- a biguanide antihyperglycaemic agent or the essentially simultaneous administration of separate formulations of each agent.
- the invention provides the use of an insulin sensitiser, such as Compound (I), and a biguanide antihyperglycaemic agent, for use in the manufacture of a composition for the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus.
- an insulin sensitiser such as Compound (I)
- a biguanide antihyperglycaemic agent for use in the manufacture of a composition for the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus.
- a suitable biguanide antihyperglycaemic agent is metformin, buformin or phenformin, especially metformin.
- a suitable thiazolidinedione insulin sensitiser is Compound (I).
- thiazolidinedione insulin sensitisers include (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (or englitazone)
- the method comprises the administration of 2 to 12 mg of Compound (I), especially when administered per day.
- the method comprises the administration of 2 to 4 , 4 to 8 or 8 to 12 mg of Compound (I) per day.
- the method comprises the administration of 2 to 4 mg of Compound (I), especially when administered per day.
- the method comprises the administration of 4 to 8 mg of Compound (I), especially when administered per day.
- the method comprises the administration of 8 to 12 mg of Compound (I), especially when administered per day.
- the method comprises the administration of 2 mg of Compound (I), especially when administered per day.
- the method comprises the administration of 4 mg of Compound (I), especially when administered per day.
- the method comprises the administration of 8 mg of Compound (I), especially when administered per day.
- the insulin sensitiser such as Compound (I) and the biguanide antihyperglycaemic agent are each administered in a pharmaceutically acceptable form, including pharmaceutically acceptable derivatives such as pharmaceutically acceptable salts, esters and solvates thereof, as appropriate of the relevant pharmaceutically active agent.
- pharmaceutically acceptable derivatives such as pharmaceutically acceptable salts, esters and solvates thereof, as appropriate of the relevant pharmaceutically active agent.
- the names used for the relevant biguanide may relate to a particular pharmaceutical form of the relevant active agent: It will be understood that all pharmaceutically acceptable forms of the active agents per se are encompassed by this invention.
- Suitable pharmaceutically acceptable forms of insulin sensitisers include those described in the above mentioned publications.
- Suitable pharmaceutically acceptable forms of Compound (I) include those described in EP 0306228 and WO94/05659, especially pharmaceutically acceptable salted forms.
- a preferred pharmaceutically acceptable salt is a maleate.
- Suitable pharmaceutically acceptable solvated forms of Compound (I) include those described in EP 0306228 and WO94/05659, in particular hydrates.
- Suitable pharmaceutically acceptable forms of the biguanide antihyperglycaemic agent depend upon the particular agent used but includes known pharmaceutically acceptable forms of the particular compound chosen. Such derivatives are found or are referred to in standard reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein).
- a suitable pharmaceutically acceptable form of metformin is an acid addition salt, such as a hydrochloride.
- Compound (I) or, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof may be prepared using known methods, for example those disclosed in EP 0306228 and WO94/05659. The disclosures of EP 0306228 and WO94/05659 are incorporated herein by reference.
- Compound (I) may exist in one of several tautomeric forms, all of which are encompassed by the term Compound (I) as individual tautomeric forms or as mixtures thereof.
- Compound (I) contains a chiral carbon atom, and hence can exist in up to two stereoisomeric forms, the term Compound (I) encompasses all of these isomeric forms whether as individual isomers or as mixtures of isomers, including racemates.
- the insulin sensitiser or the biguanide antihyperglycaemic agent of choice is prepared according to known methods, such methods are found or are referred to in standard reference texts, such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) or as described in the above mentioned publications.
- condition associated with diabetes includes those conditions associated with the pre-diabetic state, conditions associated with diabetes mellitus itself and complications associated with diabetes mellitus.
- condition associated with the pre-diabetic state includes conditions such as insulin resistance, including hereditary insulin resistance, impaired glucose tolerance and hyperinsulinaemia.
- Constants associated with diabetes mellitus itself include hyperglycaemia, insulin resistance, including acquired insulin resistance and obesity. Further conditions associated with diabetes mellitus itself include hypertension and cardiovascular disease, especially atherosclerosis and conditions associated with insulin resistance. Conditions associated with insulin resistance include polycystic ovarian syndrome and steroid induced insulin resistance and gestational diabetes.
- Complications associated with diabetes mellitus includes renal disease, especially renal disease associated with Type II diabetes, neuropathy and retinopathy.
- Renal diseases associated with Type II diabetes include nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease.
- the term ‘pharmaceutically acceptable’ embraces both human and veterinary use: for example the term ‘pharmaceutically acceptable’ embraces a veterinarily acceptable compound.
- scalar amounts including mg amounts, of Compound (I) in a pharmaceutically acceptable form
- the scalar amount referred to is made in respect of Compound (I) per se:
- 2 mg of Compound (I) in the form of the maleate salt is that amount of maleate salt which contains 2 mg of Compound (I).
- Diabetes mellitus is preferably Type II diabetes.
- the particularly beneficial effect on glycaemic control provided by the treatment of the invention is indicated to be a synergistic effect relative to the control expected for the sum of the effects of the individual active agents.
- Glycaemic control may be characterised using conventional methods, for example by measurement of a typically used index of glycaemic control such as fasting plasma glucose or glycosylated haemoglobin (Hb Alc). Such indices are determined using standard methodology, for example those described in: Tuescher A, Richterich, P., Sau. med. Wschr. 101 (1971), 345 and 390 and Frank P., ‘Monitoring the Diabetic Patent with Glycosolated Hemoglobin Measurements’, Clinical Products 1988.
- a typically used index of glycaemic control such as fasting plasma glucose or glycosylated haemoglobin (Hb Alc).
- Hb Alc glycosylated haemoglobin
- the dosage level of each of the active agents when used in accordance with the treatment of the invention will be less than would have been required from a purely additive effect upon glycaemic control.
- the treatment of the invention will effect an improvement, relative to the individual agents, in the levels of advanced glycosylation end products (AGEs), leptin and serum lipids including total cholesterol, HDL-cholesterol, LDL-cholesterol including improvements in the ratios thereof, in particular an improvement in serum lipids including total cholesterol, HDL-cholesterol, LDL-cholesterol including improvements in the ratios thereof.
- AGEs advanced glycosylation end products
- leptin and serum lipids including total cholesterol, HDL-cholesterol, LDL-cholesterol including improvements in the ratios thereof in particular an improvement in serum lipids including total cholesterol, HDL-cholesterol, LDL-cholesterol including improvements in the ratios thereof.
- the active medicaments are preferably administered in pharmaceutical composition form.
- such compositions can include both medicaments or one only of the medicaments.
- a pharmaceutical composition comprising an insulin sensitiser, such as Compound (I) especially 2 to 12 mg thereof, a biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor.
- compositions may be prepared by admixing an insulin sensitiser, such as Compound (I) especially 2 to 12 mg thereof, the biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor.
- an insulin sensitiser such as Compound (I) especially 2 to 12 mg thereof
- the biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor.
- compositions are adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration, sublingual or transdermal administration.
- compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
- composition of the invention is in the form of a unit dose.
- Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.
- binding agents for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone
- fillers for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine
- tabletting lubricants for example magnesium stearate
- disintegrants for example star
- compositions are preferably in a unit dosage form in an amount appropriate for the relevant daily dosage.
- Suitable unit dosages of the Compound of formula (I) comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg of Compound (I).
- composition of the invention may be administered from 1 to 6 times a day, but most preferably 1 or 2 times per day.
- Particular dosages of Compound (I) are 2 mg/day, 4 mg/day, including 2 mg twice per day, and 8 mg/day, including 4 mg twice per day.
- Suitable unit dosages of the insulin sensitiser or the biguanide antihyperglycaemic agent, such as metformin include the known doses for these compounds as described or referred to in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) or the above mentioned publications.
- Suitable dosages of metformin include up to 3000 mg per day, in unit doses of 500 mg (for example two or three times per day) or 850 mg (for example two times per day), one example of a dosage for metformin is 500 mg once building to five times per day per day.
- one example of the method comprises the administration of 4 or 8 mg of Compound (I) (at 2 mg twice per day or 4 mg twice per day respectively) and 1000 mg or 2500 mg of metformin (at 500 mg twice per day or 500 mg five times per day respectively).
- the solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art.
- the tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
- Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
- Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
- suspending agents for example sorbitol, syrup, methyl cellulose,
- fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle.
- the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing.
- adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle.
- the composition can be frozen after filling into the vial and the water removed under vacuum.
- Parenteral suspensions are prepared in substantially the same manner, except that the Compound (I)s suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration.
- the compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle.
- a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
- Compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration.
- compositions may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
- compositions are formulated according to conventional methods, such as those disclosed in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) and Harry's Cosmeticology (Leonard Hill Books).
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising an insulin sensitiser such as Compound (I) especially 2 to 12 mg thereof, a biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor, for use as an active therapeutic substance.
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising an insulin sensitiser such as Compound (I) especially 2 to 12 mg thereof, a biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor, for use in the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus.
- an insulin sensitiser such as Compound (I) especially 2 to 12 mg thereof
- a biguanide antihyperglycaemic agent especially a pharmaceutically acceptable carrier therefor
- a range of 2 to 4 mg includes a range of 2.1 to 4, 2.2 to 4, 2.3 to 4, 2.4 to 4, 2.5 to 4, 2.6 to 4, 2.7 to 4, 2.8 to 4, 2.9 to 4 or 3 to 4 mg.
- a range of 4 to 8 mg includes a range of 4.1 to 8, 4.2 to 8, 4.3 to 8, 4.4 to 8, 4.5 to 8, 4.6 to 8, 4.7 to 8, 4.8 to 8, 4.9 to 8, 5 to 8, 6 to 8 or 7 to 8 mg.
- a range of 8 to 12 mg includes a range of 8.1 to 12, 8.2 to 12, 8.3 to 12, 8.4 to 12, 8.5 to 12, 8.6 to 12, 8.7 to 12, 8.8 to 12, 8.9 to 12, 9 to 12, 10 to 12 or 11 to 12 mg.
- PK pharmacokinetics
- M metformin
- lactose monohydrate is passed through a suitable screen and blended with the milled maleate salt of Compound (I).
- Sodium starch glycollate, hydoxypropyl methylcellulose, microcrystalline cellulose and the remaining lactose are passed through a suitable screen and added to the mixture. Blending is then continued.
- the resulting mixture is then wet granulated with purified water.
- the wet granules are then screened, dried on a fluid bed drier and the dried granules are passed through a further screen and finally homogenised.
- Tablet cores are then transferred to a tablet coating machine, pre-warmed with warm air (approximately 65° C.) and film coated until the tablet weight has increased by 2.0% to 3.5%.
- Quantity (mg per Tablet) Tablet Strength 1.0 mg 2.0 mg 4.0 mg 8.0 mg Active Ingredient: Compound (I) maleate Concentrate 10.00 20.00 40.00 80.00 granules Other Ingredients: Sodium Starch Glycollate 6.96 6.46 5.46 10.92 Microcrystalline Cellulose 27.85 25.85 21.85 43.70 Lactose monohydrate 104.44 96.94 81.94 163.88 Magnesium Stearate 0.75 0.75 0.75 1.50 Total Weight of Tablet Core 150.0 150.0 150.0 300.0 Aqueous film coating material 4.5 4.5 4.5 9.0 Total Weight of Film Coated 154.5 154.5 154.5 309.0 Tablet
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A method for the treatment and/or prophylaxis of diabetes mellitus, conditions associated with diabetes mellitus and certain complications thereof, in a mammal which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and a biguanide antihyperglycaemic agent, to a mammal in need thereof and a pharmaceutical composition comprising an insulin sensitiser and a biguanide antihyperglycaemic agent.
Description
- This application is a continuation of application Ser. No. 11/302,999, filed Dec. 14, 2005, which is a continuation of application Ser. No. 10/947,166, filed Sep. 23, 2004, which is a continuation of application Ser. No. 10/340,426, filed Jan. 10, 2003, which is a continuation of application Ser. No. 10/099,161, filed Mar. 13, 2002 (abandoned), which is a continuation of application Ser. No. 09/925,394, filed Aug. 9, 2001 (abandoned), which is a continuation of application Ser. No. 09/446,030, filed Dec. 15, 1999 (abandoned), which is a 371 of International Application No. PCT/EP98/03690, filed Jun. 15, 1998, which claims priority to Great Britain Application Nos. 9712857.3, filed Jun. 18, 1997 and 9806706.9, filed Mar. 27, 1998.
- This invention relates to a method of treatment, in particular to a method for the treatment of diabetes mellitus, especially non-insulin dependent diabetes (NIDDM) or Type II diabetes and conditions associated with diabetes mellitus.
- Biguanide antihyperglycaemic agents are commonly used in the treatment of NIDDM (or Type II diabetes). 1,1-Dimethylbiguanidine (or Metformin) is an example of a biguanides antihyperglycaemic agent.
- European Patent Application, Publication Number 0,306,228 relates to certain thiazolidinedione derivatives disclosed as having antihyperglycaemic and hypolipidaemic activity. One particular thiazolidinedione disclosed in EP 0306228 is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl]thiazolidine-2,4-dione (hereinafter ‘Compound (I)’). WO94/05659 discloses certain salts of Compound (I) including the maleate salt at example 1 thereof.
- Compound (I) is an example of a class of anti-hyperglycaemic agents known as ‘insulin sensitisers’. In particular Compound (I) is a thiazolidinedione insulin sensitiser.
- European Patent Applications, Publication Numbers: 0008203, 0139421, 0032128, 0428312, 0489663, 0155845, 0257781, 0208420, 0177353, 0319189, 0332331, 0332332, 0528734, 0508740; International Patent Application, Publication Numbers 92/18501, 93/02079, 93/22445 and U.S. Pat. Nos. 5,104,888 and 5,478,852, also disclose certain thiazolidinedione insulin sensitisers.
- Another series of compounds generally recognised as having insulin sensitiser activity are those typified by the compounds disclosed in International Patent Applications, Publication Numbers WO93/21166 and WO94/01420. These compounds are herein referred to as ‘acyclic insulin sensitisers’. Other examples of acyclic insulin sensitisers are those disclosed in U.S. Pat. No. 5,232,945 and International Patent Applications, Publication Numbers WO92/03425 and WO91/19702.
- Examples of other insulin sensitisers are those disclosed in European Patent Application, Publication Number 0533933, Japanese Patent Application Publication Number 05271204 and U.S. Pat. No. 5,264,451.
- The above mentioned publications are incorporated herein by reference.
- It is now surprisingly indicated that Compound (I) in combination with a biguanide antihyperglycaemic agent provides a particularly beneficial effect on glycaemic control with no observed adverse effects, such combination is therefore particularly useful for the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus.
- Accordingly, the invention provides a method for the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus in a mammal, such as a human, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser, such as Compound (I), and a biguanide antihyperglycaemic agent, to a mammal in need thereof.
- In another aspect the invention provides an insulin sensitiser, such as Compound (I), together with a biguanide antihyperglycaemic agent, for use in a method for the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus.
- The method comprises either co-administration of an insulin sensitiser, such as Compound (I), and a biguanide antihyperglycaemic agent or the sequential administration thereof.
- Co-administration includes administration of a formulation which includes both an insulin sensitiser, such as Compound (I), and a biguanide antihyperglycaemic agent or the essentially simultaneous administration of separate formulations of each agent.
- In another aspect the invention provides the use of an insulin sensitiser, such as Compound (I), and a biguanide antihyperglycaemic agent, for use in the manufacture of a composition for the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus.
- A suitable biguanide antihyperglycaemic agent is metformin, buformin or phenformin, especially metformin.
- A suitable thiazolidinedione insulin sensitiser is Compound (I).
- Other suitable thiazolidinedione insulin sensitisers include (+)-5-[[4-[(3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-yl)methoxy]phenyl]methyl]-2,4-thiazolidinedione (or troglitazone), 5-[4-[(1-methylcyclohexyl)methoxy]benzyl] thiazolidine-2,4-dione (or ciglitazone), 5-[4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl] thiazolidine-2,4-dione (or pioglitazone) or 5-[(2-benzyl-2,3-dihydrobenzopyran)-5-ylmethyl)thiazolidine-2,4-dione (or englitazone)
- In one particular aspect, the method comprises the administration of 2 to 12 mg of Compound (I), especially when administered per day.
- Particularly, the method comprises the administration of 2 to 4 , 4 to 8 or 8 to 12 mg of Compound (I) per day.
- Particularly, the method comprises the administration of 2 to 4 mg of Compound (I), especially when administered per day.
- Particularly, the method comprises the administration of 4 to 8 mg of Compound (I), especially when administered per day.
- Particularly, the method comprises the administration of 8 to 12 mg of Compound (I), especially when administered per day.
- Preferably, the method comprises the administration of 2 mg of Compound (I), especially when administered per day.
- Preferably, the method comprises the administration of 4 mg of Compound (I), especially when administered per day.
- Preferably, the method comprises the administration of 8 mg of Compound (I), especially when administered per day.
- It will be understood that the insulin sensitiser, such as Compound (I) and the biguanide antihyperglycaemic agent are each administered in a pharmaceutically acceptable form, including pharmaceutically acceptable derivatives such as pharmaceutically acceptable salts, esters and solvates thereof, as appropriate of the relevant pharmaceutically active agent. In certain instances herein the names used for the relevant biguanide may relate to a particular pharmaceutical form of the relevant active agent: It will be understood that all pharmaceutically acceptable forms of the active agents per se are encompassed by this invention.
- Suitable pharmaceutically acceptable forms of insulin sensitisers include those described in the above mentioned publications.
- Suitable pharmaceutically acceptable forms of Compound (I) include those described in EP 0306228 and WO94/05659, especially pharmaceutically acceptable salted forms. A preferred pharmaceutically acceptable salt is a maleate.
- Suitable pharmaceutically acceptable solvated forms of Compound (I) include those described in EP 0306228 and WO94/05659, in particular hydrates.
- Suitable pharmaceutically acceptable forms of the biguanide antihyperglycaemic agent depend upon the particular agent used but includes known pharmaceutically acceptable forms of the particular compound chosen. Such derivatives are found or are referred to in standard reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein).
- A suitable pharmaceutically acceptable form of metformin is an acid addition salt, such as a hydrochloride.
- Compound (I) or, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, may be prepared using known methods, for example those disclosed in EP 0306228 and WO94/05659. The disclosures of EP 0306228 and WO94/05659 are incorporated herein by reference.
- Compound (I) may exist in one of several tautomeric forms, all of which are encompassed by the term Compound (I) as individual tautomeric forms or as mixtures thereof. Compound (I) contains a chiral carbon atom, and hence can exist in up to two stereoisomeric forms, the term Compound (I) encompasses all of these isomeric forms whether as individual isomers or as mixtures of isomers, including racemates.
- The insulin sensitiser or the biguanide antihyperglycaemic agent of choice is prepared according to known methods, such methods are found or are referred to in standard reference texts, such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) or as described in the above mentioned publications.
- When used herein the term ‘conditions associated with diabetes’ includes those conditions associated with the pre-diabetic state, conditions associated with diabetes mellitus itself and complications associated with diabetes mellitus.
- When used herein the term ‘conditions associated with the pre-diabetic state’ includes conditions such as insulin resistance, including hereditary insulin resistance, impaired glucose tolerance and hyperinsulinaemia.
- ‘Conditions associated with diabetes mellitus itself’0 include hyperglycaemia, insulin resistance, including acquired insulin resistance and obesity. Further conditions associated with diabetes mellitus itself include hypertension and cardiovascular disease, especially atherosclerosis and conditions associated with insulin resistance. Conditions associated with insulin resistance include polycystic ovarian syndrome and steroid induced insulin resistance and gestational diabetes.
- ‘Complications associated with diabetes mellitus’ includes renal disease, especially renal disease associated with Type II diabetes, neuropathy and retinopathy.
- Renal diseases associated with Type II diabetes include nephropathy, glomerulonephritis, glomerular sclerosis, nephrotic syndrome, hypertensive nephrosclerosis and end stage renal disease.
- As used herein the term ‘pharmaceutically acceptable’ embraces both human and veterinary use: for example the term ‘pharmaceutically acceptable’ embraces a veterinarily acceptable compound.
- For the avoidance of doubt, when reference is made herein to scalar amounts, including mg amounts, of Compound (I) in a pharmaceutically acceptable form, the scalar amount referred to is made in respect of Compound (I) per se: For example 2 mg of Compound (I) in the form of the maleate salt is that amount of maleate salt which contains 2 mg of Compound (I).
- Diabetes mellitus is preferably Type II diabetes.
- The particularly beneficial effect on glycaemic control provided by the treatment of the invention is indicated to be a synergistic effect relative to the control expected for the sum of the effects of the individual active agents.
- Glycaemic control may be characterised using conventional methods, for example by measurement of a typically used index of glycaemic control such as fasting plasma glucose or glycosylated haemoglobin (Hb Alc). Such indices are determined using standard methodology, for example those described in: Tuescher A, Richterich, P., Schweiz. med. Wschr. 101 (1971), 345 and 390 and Frank P., ‘Monitoring the Diabetic Patent with Glycosolated Hemoglobin Measurements’, Clinical Products 1988.
- In a preferred aspect, the dosage level of each of the active agents when used in accordance with the treatment of the invention will be less than would have been required from a purely additive effect upon glycaemic control.
- There is also an indication that the treatment of the invention will effect an improvement, relative to the individual agents, in the levels of advanced glycosylation end products (AGEs), leptin and serum lipids including total cholesterol, HDL-cholesterol, LDL-cholesterol including improvements in the ratios thereof, in particular an improvement in serum lipids including total cholesterol, HDL-cholesterol, LDL-cholesterol including improvements in the ratios thereof.
- In the method of the invention, the active medicaments are preferably administered in pharmaceutical composition form. As indicated above, such compositions can include both medicaments or one only of the medicaments.
- Accordingly, in one aspect of the invention there is provided a pharmaceutical composition comprising an insulin sensitiser, such as Compound (I) especially 2 to 12 mg thereof, a biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor.
- Such compositions may be prepared by admixing an insulin sensitiser, such as Compound (I) especially 2 to 12 mg thereof, the biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor.
- Usually the compositions are adapted for oral administration. However, they may be adapted for other modes of administration, for example parenteral administration, sublingual or transdermal administration.
- The compositions may be in the form of tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
- In order to obtain consistency of administration it is preferred that a composition of the invention is in the form of a unit dose.
- Unit dose presentation forms for oral administration may be tablets and capsules and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrrolidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate; disintegrants, for example starch, polyvinylpyrrolidone, sodium starch glycollate or microcrystalline cellulose; or pharmaceutically acceptable wetting agents such as sodium lauryl sulphate.
- The compositions are preferably in a unit dosage form in an amount appropriate for the relevant daily dosage.
- Suitable unit dosages of the Compound of formula (I) comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 mg of Compound (I).
- The composition of the invention may be administered from 1 to 6 times a day, but most preferably 1 or 2 times per day.
- Particular dosages of Compound (I) are are 2 mg/day, 4 mg/day, including 2 mg twice per day, and 8 mg/day, including 4 mg twice per day.
- Suitable unit dosages of the insulin sensitiser or the biguanide antihyperglycaemic agent, such as metformin, include the known doses for these compounds as described or referred to in reference texts such as the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) or the above mentioned publications.
- Suitable dosages of metformin include up to 3000 mg per day, in unit doses of 500 mg (for example two or three times per day) or 850 mg (for example two times per day), one example of a dosage for metformin is 500 mg once building to five times per day per day.
- Thus, one example of the method comprises the administration of 4 or 8 mg of Compound (I) (at 2 mg twice per day or 4 mg twice per day respectively) and 1000 mg or 2500 mg of metformin (at 500 mg twice per day or 500 mg five times per day respectively).
- The solid oral compositions may be prepared by conventional methods of blending, filling or tabletting. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are of course conventional in the art. The tablets may be coated according to methods well known in normal pharmaceutical practice, in particular with an enteric coating.
- Oral liquid preparations may be in the form of, for example, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminium stearate gel, hydrogenated edible fats; emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid; and if desired conventional flavouring or colouring agents.
- For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, and, depending on the concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilized before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, a preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the Compound (I)s suspended in the vehicle instead of being dissolved, and sterilization cannot be accomplished by filtration. The compound can be sterilized by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
- Compositions may contain from 0.1% to 99% by weight, preferably from 10-60% by weight, of the active material, depending upon the method of administration.
- Compositions may, if desired, be in the form of a pack accompanied by written or printed instructions for use.
- The compositions are formulated according to conventional methods, such as those disclosed in standard reference texts, for example the British and US Pharmacopoeias, Remington's Pharmaceutical Sciences (Mack Publishing Co.), Martindale The Extra Pharmacopoeia (London, The Pharmaceutical Press) (for example see the 31st Edition page 341 and pages cited therein) and Harry's Cosmeticology (Leonard Hill Books).
- In a further aspect, the present invention also provides a pharmaceutical composition comprising an insulin sensitiser such as Compound (I) especially 2 to 12 mg thereof, a biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor, for use as an active therapeutic substance.
- In particular, the present invention provides a pharmaceutical composition comprising an insulin sensitiser such as Compound (I) especially 2 to 12 mg thereof, a biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor, for use in the treatment of diabetes mellitus, especially Type II diabetes and conditions associated with diabetes mellitus.
- A range of 2 to 4 mg includes a range of 2.1 to 4, 2.2 to 4, 2.3 to 4, 2.4 to 4, 2.5 to 4, 2.6 to 4, 2.7 to 4, 2.8 to 4, 2.9 to 4 or 3 to 4 mg.
- A range of 4 to 8 mg includes a range of 4.1 to 8, 4.2 to 8, 4.3 to 8, 4.4 to 8, 4.5 to 8, 4.6 to 8, 4.7 to 8, 4.8 to 8, 4.9 to 8, 5 to 8, 6 to 8 or 7 to 8 mg.
- A range of 8 to 12 mg includes a range of 8.1 to 12, 8.2 to 12, 8.3 to 12, 8.4 to 12, 8.5 to 12, 8.6 to 12, 8.7 to 12, 8.8 to 12, 8.9 to 12, 9 to 12, 10 to 12 or 11 to 12 mg.
- No adverse toxicological effects have been established for the compositions or methods of the invention in the abovementioned dosage ranges.
- The following example illustrates the invention but does not limit it in any way.
- This study evaluated the pharmacokinetics (PK) of Compound (I) and metformin (M) administered alone and in combination. Sixteen male volunteers, aged 22 to 55 years, received oral Compound (I) (2 mg Q12h), M (500 mg Q12h), or the combination, each for 4 days. Plasma collected on day 4 of each regimen was assayed for Compound (I) and M concentrations. Oral doses of Compound (I) and M were safe and well tolerated alone or in combination. There were no episodes of hypoglycaemia and co-administration did not result in an increase in blood lactic acid concentration.
Parameter M Compound (I) [units] Alone Combn Alone Combn AUC 626 629 6508 6575 (0-12) (494-866) (418-912) (4694-8705) (4773-9230) [ng · h/ mL] Cmax 105 104 901 918 [ng/mL] (78.9-150.2) (76.5-139.2) (620-1251) (635-1344) Tmax 3.0 3.5 3.0 3.5 [hours] (2.0-4.0) (1.5-4.0) (1.0-6.0) (1.5-6.0) T½ 3.22 3.21 3.24 3.41 [hours] (2.45-5.01) (2.56-4.64) (2.56-4.19) (2.64-4.58)
Combo = Compound (I) + M coadministration
Coadministration of Compound (I) and M did not affect the steady-state pharmacokinetics (AUC(0-12), Cmax, Tmax, or T1/2) of either drug. Because M plasma concentrations were unaffected, coadministration or Compound (I) will not accentuate the concentration-dependent toxicities of M.
Compound (I) Compositions
A Concentrate Preparation - Approximately two thirds of the lactose monohydrate is passed through a suitable screen and blended with the milled maleate salt of Compound (I). Sodium starch glycollate, hydoxypropyl methylcellulose, microcrystalline cellulose and the remaining lactose are passed through a suitable screen and added to the mixture. Blending is then continued. The resulting mixture is then wet granulated with purified water. The wet granules are then screened, dried on a fluid bed drier and the dried granules are passed through a further screen and finally homogenised.
% COMPOSITION OF GRANULAR CONCENTRATE Ingredient Quantity (%) Milled Compound (I) as maleate 13.25 (pure salt maleate salt) Sodium Starch Glycollate 5.00 Hydoxypropyl Methylcellulose 5.00 2910 Microcrystalline Cellulose 20.0 Lactose Monohydrate, regular to 100 grade Purified water *
* Removed during processing.
B Formulation of the Concentrate into Tablets.
The granules from above are placed into a tumble blender. Approximately two thirds of the lactose is screened and added to the blender. The microcrystalline cellulose, sodium starch glycollate, magnesium stearate and remaining lactose are screened and added to the blender and the mixture blended together. The resulting mix is then compressed on a rotary tablet press to a target weight of 150 mg for the 1, 2 and 4 mg tablets and to a target weight of 300 mg for the 8 mg tablets. - The tablet cores are then transferred to a tablet coating machine, pre-warmed with warm air (approximately 65° C.) and film coated until the tablet weight has increased by 2.0% to 3.5%.
Quantity (mg per Tablet) Tablet Strength 1.0 mg 2.0 mg 4.0 mg 8.0 mg Active Ingredient: Compound (I) maleate Concentrate 10.00 20.00 40.00 80.00 granules Other Ingredients: Sodium Starch Glycollate 6.96 6.46 5.46 10.92 Microcrystalline Cellulose 27.85 25.85 21.85 43.70 Lactose monohydrate 104.44 96.94 81.94 163.88 Magnesium Stearate 0.75 0.75 0.75 1.50 Total Weight of Tablet Core 150.0 150.0 150.0 300.0 Aqueous film coating material 4.5 4.5 4.5 9.0 Total Weight of Film Coated 154.5 154.5 154.5 309.0 Tablet
Claims (12)
1. A method for the treatment of diabetes mellitus and conditions associated with diabetes mellitus in a mammal, which method comprises administering an effective non-toxic and pharmaceutically acceptable amount of an insulin sensitiser and a biguanide antihyperglycaemic agent, to a mammal in need thereof.
2. A method according to claim 1 , wherein the biguanide antihyperglycaemic agent is metformin.
3. A method according to claim 1 , wherein the biguanide antihyperglycaemic agent is metformin hydrochloride.
4. A method according to claim 1 , wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione.
5. A method according to claim 1 , which comprises the administration of 2 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione.
6. A method according to claim 1 , which comprises the administration of 4 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione.
7. A method according to claim 1 , which comprises the administration of 8 mg of 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione.
8. A pharmaceutical composition comprising an insulin sensitiser, a biguanide antihyperglycaemic agent and a pharmaceutically acceptable carrier therefor.
9. A composition according to claim 8 , wherein the biguanide antihyperglycaemic agent is metformin.
10. A composition according to claim 8 , wherein the biguanide antihyperglycaemic agent is metformin hydrochloride.
11. A composition according to claim 8 , which comprises 500 mg or 850 mg of metformin.
12. A composition according to claim 8 , wherein the insulin sensitiser is 5-[4-[2-(N-methyl-N-(2-pyridyl)amino)ethoxy]benzyl] thiazolidine-2,4-dione.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/469,530 US20070004780A1 (en) | 1997-06-18 | 2006-09-01 | Treatment of Diabetes with Thiazolidinedione and Metformin |
US11/953,133 US20080090881A1 (en) | 1997-06-18 | 2007-12-10 | Treatment of diabetes with thiazolidinedione and metformin |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9712857.3 | 1997-06-18 | ||
GBGB9712857.3A GB9712857D0 (en) | 1997-06-18 | 1997-06-18 | Novel method of treatment |
GBGB9806706.9A GB9806706D0 (en) | 1998-03-27 | 1998-03-27 | Novel method |
GB9806706.9 | 1998-03-27 | ||
PCT/EP1998/003690 WO1998057634A1 (en) | 1997-06-18 | 1998-06-15 | Treatment of diabetes with thiazolidinedione and metformin |
US44603099A | 1999-12-15 | 1999-12-15 | |
US09/925,394 US20020004515A1 (en) | 1997-06-18 | 2001-08-09 | Treatment of diabetes with thiazolidinedione and metformin |
US10/099,161 US20020137772A1 (en) | 1997-06-18 | 2002-03-13 | Treatment of diabetes with thiazolidinedione and metformin |
US10/340,426 US20030109553A1 (en) | 1997-06-18 | 2003-01-10 | Treatment of diabetes with thiazolidinedione and metformin |
US10/947,166 US20050059706A1 (en) | 1997-06-18 | 2004-09-23 | Treatment of diabetes with thiazolidinedione and metformin |
US11/302,999 US20060100247A1 (en) | 1997-06-18 | 2005-12-14 | Treatment of diabetes with thiazolidinedione and metformin |
US11/469,530 US20070004780A1 (en) | 1997-06-18 | 2006-09-01 | Treatment of Diabetes with Thiazolidinedione and Metformin |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/302,999 Continuation US20060100247A1 (en) | 1997-06-18 | 2005-12-14 | Treatment of diabetes with thiazolidinedione and metformin |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/953,133 Continuation US20080090881A1 (en) | 1997-06-18 | 2007-12-10 | Treatment of diabetes with thiazolidinedione and metformin |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070004780A1 true US20070004780A1 (en) | 2007-01-04 |
Family
ID=26311745
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/302,999 Abandoned US20060100247A1 (en) | 1997-06-18 | 2005-12-14 | Treatment of diabetes with thiazolidinedione and metformin |
US11/469,530 Abandoned US20070004780A1 (en) | 1997-06-18 | 2006-09-01 | Treatment of Diabetes with Thiazolidinedione and Metformin |
US11/953,133 Abandoned US20080090881A1 (en) | 1997-06-18 | 2007-12-10 | Treatment of diabetes with thiazolidinedione and metformin |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/302,999 Abandoned US20060100247A1 (en) | 1997-06-18 | 2005-12-14 | Treatment of diabetes with thiazolidinedione and metformin |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/953,133 Abandoned US20080090881A1 (en) | 1997-06-18 | 2007-12-10 | Treatment of diabetes with thiazolidinedione and metformin |
Country Status (39)
Country | Link |
---|---|
US (3) | US20060100247A1 (en) |
EP (2) | EP1787646A3 (en) |
JP (1) | JP2002504137A (en) |
KR (2) | KR100666591B1 (en) |
CN (2) | CN1230171C (en) |
AP (1) | AP1279A (en) |
AR (2) | AR012998A1 (en) |
AT (1) | ATE355840T1 (en) |
AU (1) | AU8539398A (en) |
BG (2) | BG64818B1 (en) |
BR (1) | BR9810172A (en) |
CA (1) | CA2294582C (en) |
CY (2) | CY1107643T1 (en) |
CZ (1) | CZ298469B6 (en) |
DE (2) | DE69837261T2 (en) |
DK (1) | DK0996444T3 (en) |
DZ (1) | DZ2520A1 (en) |
EA (1) | EA003144B1 (en) |
ES (1) | ES2284212T3 (en) |
HK (1) | HK1028193A1 (en) |
ID (1) | ID23372A (en) |
IL (3) | IL133142A0 (en) |
IN (1) | IN189722B (en) |
LU (1) | LU91356I2 (en) |
MA (1) | MA26512A1 (en) |
MY (1) | MY129897A (en) |
NL (1) | NL300288I2 (en) |
NO (4) | NO324993B1 (en) |
NZ (1) | NZ501260A (en) |
OA (1) | OA11516A (en) |
PE (1) | PE83199A1 (en) |
PL (2) | PL195136B1 (en) |
PT (1) | PT996444E (en) |
SI (1) | SI0996444T1 (en) |
SK (1) | SK286029B6 (en) |
TR (1) | TR199903057T2 (en) |
TW (1) | TW565449B (en) |
UY (1) | UY25049A1 (en) |
WO (1) | WO1998057634A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2459238A (en) * | 2007-03-14 | 2009-10-21 | Aptina Imaging Corp | Packaging methods for imager devices |
Families Citing this family (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2158607C2 (en) * | 1995-07-03 | 2000-11-10 | Санкио Компани Лимитед | Arteriosclerosis and xanthoma treatment |
GB9712857D0 (en) * | 1997-06-18 | 1997-08-20 | Smithkline Beecham Plc | Novel method of treatment |
ATE250418T1 (en) | 1998-07-15 | 2003-10-15 | Merck Sante Sas | TABLETS CONTAINING A COMBINATION OF GLIBENCLAMIDE AND METFORMIN |
WO2000053171A1 (en) * | 1999-03-05 | 2000-09-14 | Molteni L. E C. Dei Fratelli Alitti Societa' Di Esercizio S.P.A. | Use of metformin in the preparation of pharmaceutical compositions capable of inhibiting the enzyme dipeptidyl peptidase iv |
TWI249401B (en) | 1999-04-14 | 2006-02-21 | Takeda Chemical Industries Ltd | Agent for improving ketosis |
BR0009934A (en) | 1999-04-23 | 2002-06-04 | Smithkline Beecham Plc | Pharmaceutical |
HU229352B1 (en) | 1999-11-03 | 2013-11-28 | Bristol Myers Squibb Co | Medicament comprising the combination of metformin and glyburide |
US6586438B2 (en) * | 1999-11-03 | 2003-07-01 | Bristol-Myers Squibb Co. | Antidiabetic formulation and method |
MY125516A (en) * | 1999-11-16 | 2006-08-30 | Smithkline Beecham Plc | Novel composition based on thiazolidinedione and metformin and use |
WO2001035940A2 (en) * | 1999-11-16 | 2001-05-25 | Smithkline Beecham P.L.C. | Pharmaceutical composition comprising a thiazolidinedione-metformin hydrochloride |
US20010036479A1 (en) | 2000-01-14 | 2001-11-01 | Gillian Cave | Glyburide composition |
GB0006133D0 (en) | 2000-03-14 | 2000-05-03 | Smithkline Beecham Plc | Novel pharmaceutical |
DE60129425T2 (en) * | 2000-05-01 | 2008-04-17 | Aeropharm Technology LLC, Dover | CORE FORMULATION |
FR2812547B1 (en) * | 2000-08-04 | 2002-10-31 | Lipha | PHARMACEUTICAL COMPOSITION COMPRISING A METFORMIN AND THIAZOLIDINEDIONION DERIVATIVE AND ITS USE FOR THE PREPARATION OF MEDICINES FOR TREATING DIABETES |
EP1349531A1 (en) | 2001-01-12 | 2003-10-08 | Sun Pharmaceuticals Industries Ltd. | Spaced drug delivery system |
FR2838968A1 (en) * | 2002-04-30 | 2003-10-31 | Lipha | ASSOCIATION OF INSULIN AND A THIAZOLIDINEDIONE DERIVATIVE AND USE THEREOF FOR TREATING DIABETES |
EP1515701B1 (en) | 2002-06-17 | 2014-09-17 | Inventia Healthcare Private Limited | Process for the manufacture of multilayer tablet compositions comprising thiazolidinedione and biguanide |
KR20120034211A (en) * | 2002-09-20 | 2012-04-10 | 안드렉스 랩스 엘엘씨 | Pharmaceutical tablet |
UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
NZ541749A (en) | 2003-01-29 | 2009-06-26 | Takeda Pharmaceutical | Process for producing coated preparation comprising pioglitazone hydrochloride and a coating material |
US8263121B2 (en) | 2004-04-14 | 2012-09-11 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical preparation |
CN1327840C (en) * | 2004-06-08 | 2007-07-25 | 天津药物研究院 | Medicinal composition and its use in treatment of diabetes |
WO2006011397A1 (en) * | 2004-07-27 | 2006-02-02 | Kowa Company., Ltd. | Drug for prevention or treatment of diabetes |
US20070032420A1 (en) * | 2005-02-09 | 2007-02-08 | Entelos, Inc. | Treating diabetes with glucagon-like peptide-1 secretagogues |
JPWO2007007757A1 (en) * | 2005-07-12 | 2009-01-29 | 第一三共株式会社 | Pharmaceutical composition containing a PPARγ agonist |
US7435741B2 (en) | 2006-05-09 | 2008-10-14 | Teva Pharmaceutical Industries, Ltd. | 2-N{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2,4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
EP2270007A1 (en) * | 2006-05-09 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | 2-N-{5-[[4-[2-(methyl-2-pyridinylamino) ethoxy] phenyl]methyl]-2-4-thiazolidinedione} butanedioic acid, methods of preparation and compositions with rosiglitazone maleate |
CN101069745B (en) * | 2006-05-12 | 2010-07-21 | 北京华安佛医药研究中心有限公司 | Medicine composition for treating 2-type diabetes |
EP2313360B1 (en) * | 2008-07-28 | 2012-09-05 | Syddansk Universitet | Compounds for the treatment of metabolic diseases |
DE102009053562A1 (en) | 2009-11-18 | 2011-05-19 | Alfred E. Tiefenbacher (Gmbh & Co. Kg) | Pharmaceutical composition, useful for treating diabetes mellitus type 2 in a combination therapy with other antidiabetic agent, comprises rosiglitazone succinate as an active agent |
US8796338B2 (en) | 2011-01-07 | 2014-08-05 | Elcelyx Therapeutics, Inc | Biguanide compositions and methods of treating metabolic disorders |
MX2013007884A (en) | 2011-01-07 | 2013-09-13 | Elcelyx Therapeutics Inc | Chemosensory receptor ligand-based therapies. |
US9572784B2 (en) | 2011-01-07 | 2017-02-21 | Elcelyx Therapeutics, Inc. | Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk |
US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9480663B2 (en) | 2011-01-07 | 2016-11-01 | Elcelyx Therapeutics, Inc. | Biguanide compositions and methods of treating metabolic disorders |
US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
AU2012363873B2 (en) | 2012-01-06 | 2017-11-23 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
CN110693867A (en) | 2012-01-06 | 2020-01-17 | 埃尔舍利克斯治疗公司 | Compositions and methods for treating metabolic disorders |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4895862A (en) * | 1989-04-21 | 1990-01-23 | American Home Products Corp. | Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
US5068342A (en) * | 1989-10-27 | 1991-11-26 | American Home Products Corporation | 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US5900435A (en) * | 1991-08-26 | 1999-05-04 | Pharmacia & Upjohn Company | Composition, food product and uses of 3-guanidinopropionic acid |
US5952973A (en) * | 1996-04-01 | 1999-09-14 | Honda Giken Kogyo Kabushiki Kaisha | Planar antenna module |
US5952356A (en) * | 1995-06-20 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition |
US6031004A (en) * | 1997-12-08 | 2000-02-29 | Bristol-Myers Squibb Company | Salts of metformin and method |
US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
US6297269B1 (en) * | 1995-06-06 | 2001-10-02 | Pfizer Inc. | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
US20020016287A1 (en) * | 1997-07-18 | 2002-02-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
US20020177612A1 (en) * | 1997-06-05 | 2002-11-28 | Smithkline Beecham P.I.C. | Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5522636A (en) * | 1978-08-04 | 1980-02-18 | Takeda Chem Ind Ltd | Thiazoliding derivative |
JPS5697277A (en) * | 1980-01-07 | 1981-08-05 | Takeda Chem Ind Ltd | Thiazolidine derivative |
JPS6051189A (en) * | 1983-08-30 | 1985-03-22 | Sankyo Co Ltd | Thiazolidine derivative and its preparation |
CN1003445B (en) * | 1984-10-03 | 1989-03-01 | 武田药品工业株式会社 | The preparation method of thiazolidine diketone derivative |
JPH06779B2 (en) * | 1985-06-10 | 1994-01-05 | 武田薬品工業株式会社 | Thiazolidione derivative and pharmaceutical composition comprising the same |
US4812570A (en) * | 1986-07-24 | 1989-03-14 | Takeda Chemical Industries, Ltd. | Method for producing thiazolidinedione derivatives |
ES2137915T3 (en) * | 1987-09-04 | 2000-01-01 | Beecham Group Plc | DERIVATIVES OF TIAZOLIDINDIONA SUBSTITUTED. |
WO1991007107A1 (en) * | 1989-11-13 | 1991-05-30 | Pfizer Inc. | Oxazolidinedione hypoglycemic agents |
JPH04210683A (en) * | 1990-12-06 | 1992-07-31 | Terumo Corp | Thiazolidine-2,4-dione derivative and treating agent for diabetic complication containing the same derivative |
GB9218830D0 (en) * | 1992-09-05 | 1992-10-21 | Smithkline Beecham Plc | Novel compounds |
EP1555845A1 (en) * | 2004-01-15 | 2005-07-20 | Siemens Aktiengesellschaft | Method for location determination of subscriber stations of a radio communications system |
-
1998
- 1998-06-15 CZ CZ0457899A patent/CZ298469B6/en not_active IP Right Cessation
- 1998-06-15 AT AT98936364T patent/ATE355840T1/en active
- 1998-06-15 SI SI9830883T patent/SI0996444T1/en unknown
- 1998-06-15 KR KR1019997011865A patent/KR100666591B1/en not_active IP Right Cessation
- 1998-06-15 ES ES98936364T patent/ES2284212T3/en not_active Expired - Lifetime
- 1998-06-15 AU AU85393/98A patent/AU8539398A/en not_active Abandoned
- 1998-06-15 JP JP50375599A patent/JP2002504137A/en active Pending
- 1998-06-15 EP EP07103607A patent/EP1787646A3/en not_active Withdrawn
- 1998-06-15 EP EP98936364A patent/EP0996444B1/en not_active Revoked
- 1998-06-15 EA EA200000041A patent/EA003144B1/en not_active IP Right Cessation
- 1998-06-15 CN CNB021561281A patent/CN1230171C/en not_active Expired - Fee Related
- 1998-06-15 PT PT98936364T patent/PT996444E/en unknown
- 1998-06-15 CA CA002294582A patent/CA2294582C/en not_active Expired - Fee Related
- 1998-06-15 SK SK1792-99A patent/SK286029B6/en not_active IP Right Cessation
- 1998-06-15 PL PL98377980A patent/PL195136B1/en not_active IP Right Cessation
- 1998-06-15 DK DK98936364T patent/DK0996444T3/en active
- 1998-06-15 IL IL13314298A patent/IL133142A0/en unknown
- 1998-06-15 NZ NZ501260A patent/NZ501260A/en unknown
- 1998-06-15 BR BR9810172-2A patent/BR9810172A/en not_active Application Discontinuation
- 1998-06-15 WO PCT/EP1998/003690 patent/WO1998057634A1/en active IP Right Grant
- 1998-06-15 CN CN98806224A patent/CN1114404C/en not_active Expired - Lifetime
- 1998-06-15 TR TR1999/03057T patent/TR199903057T2/en unknown
- 1998-06-15 KR KR1020067019737A patent/KR20060105005A/en not_active Application Discontinuation
- 1998-06-15 PL PL98337362A patent/PL195140B1/en not_active IP Right Cessation
- 1998-06-15 AP APAP/P/1999/001719A patent/AP1279A/en active
- 1998-06-15 DE DE69837261T patent/DE69837261T2/en not_active Expired - Lifetime
- 1998-06-15 DE DE200712000054 patent/DE122007000054I1/en active Pending
- 1998-06-15 ID IDW991629A patent/ID23372A/en unknown
- 1998-06-17 DZ DZ980130A patent/DZ2520A1/en active
- 1998-06-17 AR ARP980102884A patent/AR012998A1/en unknown
- 1998-06-17 AR ARP980102880A patent/AR012995A1/en unknown
- 1998-06-17 MA MA25123A patent/MA26512A1/en unknown
- 1998-06-17 MY MYPI98002711A patent/MY129897A/en unknown
- 1998-06-17 TW TW087109617A patent/TW565449B/en not_active IP Right Cessation
- 1998-06-18 IN IN1694DE1998 patent/IN189722B/en unknown
- 1998-06-18 UY UY25049A patent/UY25049A1/en not_active Application Discontinuation
- 1998-06-18 PE PE1998000534A patent/PE83199A1/en not_active Application Discontinuation
-
1999
- 1999-11-25 IL IL133142A patent/IL133142A/en unknown
- 1999-12-17 NO NO19996266A patent/NO324993B1/en not_active IP Right Cessation
- 1999-12-17 OA OA9900294A patent/OA11516A/en unknown
-
2000
- 2000-01-06 BG BG10406A patent/BG64818B1/en unknown
- 2000-01-06 BG BG109398A patent/BG109398A/en unknown
- 2000-10-25 HK HK00106802A patent/HK1028193A1/en not_active IP Right Cessation
-
2005
- 2005-12-14 US US11/302,999 patent/US20060100247A1/en not_active Abandoned
-
2006
- 2006-02-09 IL IL173650A patent/IL173650A0/en unknown
- 2006-06-28 NO NO20063000A patent/NO326958B1/en not_active IP Right Cessation
- 2006-09-01 US US11/469,530 patent/US20070004780A1/en not_active Abandoned
-
2007
- 2007-05-31 CY CY20071100727T patent/CY1107643T1/en unknown
- 2007-08-23 CY CY2007018C patent/CY2007018I1/en unknown
- 2007-08-29 LU LU91356C patent/LU91356I2/en unknown
- 2007-08-31 NL NL300288C patent/NL300288I2/en unknown
- 2007-12-10 US US11/953,133 patent/US20080090881A1/en not_active Abandoned
-
2008
- 2008-04-03 NO NO2008003C patent/NO2008003I2/en unknown
-
2009
- 2009-02-24 NO NO20090846A patent/NO20090846L/en not_active Application Discontinuation
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4895862A (en) * | 1989-04-21 | 1990-01-23 | American Home Products Corp. | Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
US5068342A (en) * | 1989-10-27 | 1991-11-26 | American Home Products Corporation | 5-[(1- and 2-naphthalenyl)thio and sulfonyl]-2,4-thiazolidinediones and derivatives thereof |
US5900435A (en) * | 1991-08-26 | 1999-05-04 | Pharmacia & Upjohn Company | Composition, food product and uses of 3-guanidinopropionic acid |
US6297269B1 (en) * | 1995-06-06 | 2001-10-02 | Pfizer Inc. | Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors |
US5952356A (en) * | 1995-06-20 | 1999-09-14 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition |
US5965584A (en) * | 1995-06-20 | 1999-10-12 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition |
US6911459B2 (en) * | 1995-06-20 | 2005-06-28 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition |
US6150384A (en) * | 1995-06-20 | 2000-11-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition |
US6150383A (en) * | 1995-06-20 | 2000-11-21 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition |
US20040266830A1 (en) * | 1995-06-20 | 2004-12-30 | Hitoshi Ikeda | Pharmaceutical composition |
US6166043A (en) * | 1995-06-20 | 2000-12-26 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition |
US6166042A (en) * | 1995-06-20 | 2000-12-26 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition |
US5952973A (en) * | 1996-04-01 | 1999-09-14 | Honda Giken Kogyo Kabushiki Kaisha | Planar antenna module |
US5859037A (en) * | 1997-02-19 | 1999-01-12 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US5972973A (en) * | 1997-02-19 | 1999-10-26 | Warner-Lambert Company | Sulfonylurea-glitazone combinations for diabetes |
US6291495B1 (en) * | 1997-02-24 | 2001-09-18 | Robert B. Rieveley | Method and composition for the treatment of diabetes |
US6153632A (en) * | 1997-02-24 | 2000-11-28 | Rieveley; Robert B. | Method and composition for the treatment of diabetes |
US20020177612A1 (en) * | 1997-06-05 | 2002-11-28 | Smithkline Beecham P.I.C. | Composition comprising 5-[4-[2-(N-methyl-N-2-pyridy)amino)ethoxy]benzyl]thiazolidine-2,4-dione |
US20020016287A1 (en) * | 1997-07-18 | 2002-02-07 | Smithkline Beecham P.L.C. | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide |
US6031004A (en) * | 1997-12-08 | 2000-02-29 | Bristol-Myers Squibb Company | Salts of metformin and method |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2459238A (en) * | 2007-03-14 | 2009-10-21 | Aptina Imaging Corp | Packaging methods for imager devices |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20070004780A1 (en) | Treatment of Diabetes with Thiazolidinedione and Metformin | |
US20030109553A1 (en) | Treatment of diabetes with thiazolidinedione and metformin | |
US20080058388A1 (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
EP1001783B1 (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide | |
EP1001784A1 (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucosidase inhibitor | |
WO1998057635A1 (en) | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor | |
WO1998057649A1 (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea | |
US20020016287A1 (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and diguanide | |
AU778947B2 (en) | Treatment of diabetes with thiazolidinedione and metformin | |
US20030073645A1 (en) | Treatment of diabetes with thiazolidinedione and alpha-glucosidase inhibitor | |
CA2549864A1 (en) | Treatment of diabetes with thiazolidinedione and metformin | |
NZ515554A (en) | Treatment of diabetes with thiazolidinedione and metformin | |
US20030092750A1 (en) | Treatment of diabetes with thiazolidinedione, insulin secretagogue and alpha glucocidase inhibitor | |
AU1540002A (en) | Treatment of diabetes with thiazolidinedione and sulphonylurea |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |